1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Euthymics expands series A financing to work on 'next generation Straterra'

 
• By Sukaina Virji

Euthymics Bioscience has added $4 million to its series A financing to fund preclinical development of its second product candidate, EB-1020, a non-stimulant for adult attention deficit hyperactivity disorder (ADHD). The product is "a different drug altogether" from Shire's non-stimulant ADHD drug Intuniv (guanfacine), Euthymic's president and CEO, Anthony McKinney, told Scrip.

Euthymics Bioscience has added $4 million to its series A financing to fund preclinical development of its second product candidate, EB-1020, a non-stimulant for adult attention deficit hyperactivity disorder (ADHD). The product is "a different drug altogether" from Shire's non-stimulant ADHD drug Intuniv (guanfacine), Euthymic's president and CEO, Anthony McKinney, told Scrip.

"Members of our leadership team were involved in the development of the first non-stimulant developed for ADHD, Lilly's Straterra (atomoxetine),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 
• By Alaric DeArment

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 
• By Andrew McConaghie

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

More from Therapeutic Category

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.